New schizophrenia drug shows promise in hospitalized patients
NCT ID NCT07288333
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tests a new drug called NBI-1117570 to see if it can improve schizophrenia symptoms like confusion, hallucinations, and mood changes. About 120 adults aged 18 to 55 who are currently hospitalized for a schizophrenia episode will receive either the drug or a placebo. The main goal is to measure symptom changes after 35 days of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGLondon, SE5 8AZ, United Kingdom
-
Neurocrine Clinical Site
RECRUITINGOxford, OX3 7JX, United Kingdom
Conditions
Explore the condition pages connected to this study.